ArticleCureus2026
Invasive Partial Hydatidiform Mole Presenting As Cesarean Scar Pregnancy: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive hydatidiform mole is a rare subtype of gestational trophoblastic disease characterized by myometrial invasion and the potential for significant morbidity. Cesarean scar pregnancy (CSP) is an uncommon type of ectopic pregnancy with increasing incidence due to the rise in cesarean delivery rates. The coexistence of an invasive hydatidiform mole implanted in a cesarean scar is exceptionally rare and poses significant diagnostic and therapeutic challenges. This is a case of a 32-year-old Malay woman with a prior history of cesarean section who presented with per-vaginal bleeding in early pregnancy. Assessment revealed a viable gestational sac with vesicles within, suggesting that a partial hydatidiform mole had implanted at the cesarean scar site. Serum beta-human chorionic gonadotropin (β-hCG) levels were markedly elevated (>200,000 IU/L). MRI of the pelvis was reported as suggestive of partial invasive molar pregnancy with serosal breach through the cesarean scar and bladder invasion, along with a fetus seen, and proceeded with six cycles of methotrexate and folinic acid regimen. Serum β-hCG levels reduced accordingly (368 IU/L pre-sixth cycle and prior surgery). Proceeded with total abdominal hysterectomy, bilateral salpingectomy, and histopathological examination confirmed the diagnosis of an invasive hydatidiform mole arising from a CSP. The patient was managed with a multidisciplinary approach with close β-hCG surveillance. Clinical and biochemical remission was achieved. Invasive hydatidiform mole presenting as a CSP is extremely rare. Early recognition through imaging, β-hCG monitoring, and histopathology is crucial to prevent life-threatening complications. Prompt multidisciplinary management and careful follow-up are essential for favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.